Airway deposition and clearance and systemic pharmacokinetics of amiloride following aerosolization with an ultrasonic nebulizer to normal airways

Chest

Volumn 112, Issue 5, 1997, Pages 1283-1290

  Noone, Peadar G ^a,b   Regnis, Jeff A ^a   Liu, Xingrong ^b   Brouwer, Kim L R ^b   Robinson, Michael ^c   Edwards, Lloyd ^b   Knowles, Michael R ^a  

^a Cystic Fibrosis/Pulmon Res T   (Australia)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

Amiloride; Cystic fibrosis; Ultrasonic nebulizer

Indexed keywords

AMILORIDE;

ADULT; AEROSOL; AIRWAY; ARTICLE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EXCRETION; HUMAN; HUMAN EXPERIMENT; INHALATIONAL DRUG ADMINISTRATION; NEBULIZATION; NORMAL HUMAN; PRIORITY JOURNAL; URINARY EXCRETION;

EID: 0030663247     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.112.5.1283     Document Type: Article

References (43)

1. Boucher RC. Human airway ion transport (part 1). Am J Respir Crit Care Med 1994; 150:271-81
2. Boucher RC. Human airway ion transport (part 2). Am J Respir Crit Care Med 1994; 150:581-93
3. Welsh MJ, Tsui L, Boat TF. et al. Cystic fibrosis. In: Seriver CR, Beaudet AL, Sly WS, et al, eds. The metabolic and molecular bases of inherited diseases. 7th ed. New York: McGraw-Hill, 1966; 3799-876
4. Davis PB, Drumin M, Konstan MW. Cystic fibrosis - state of the art. Am J Respir Crit Care Med 1996; 154:1229-56
5. Knowles MR, Church NL, Waltner WE, et al. A pilot study of aerosolized amiloride for the treatment of lung disease in cystic fibrosis. N Engl J Med 1990; 322:1189-94
6. Tomkiewicz RP, App EM, Zayas JG, et al. Amiloride inhalation therapy in cystic fibrosis: influence on ion content, hydration, and rheology of sputum. Am Rev Respir Dis 1993; 148:1002-07
7. Olivier KN, Bennett WD, Holmeker KW, et al. Acute safety and effects on mucociliary clearance of aerosolized uridine 5′-triphosphate +/- amiloride in normal adults. Am J Respir Crit Care Med 1996; 154:217-23
8. Bennett WD, Olivier KN, Zeman, KL, et al. Effect of uridine 5′-triphosphate plus amiloride on mucociliary clearance in adult cystic fibrosis. Am J Respir Crit Care Med 1996; 153:1796-1801
9. Loffert DT, Ikle D, Nelson HS. A comparison of commercial jet nebulizers. Chest 1994; 106:1788-93
10. Waldrep JC, Keyhani K, Black M, et al. Operating characteristics of 18 different continuous-flow jet nebulizers with beclomethasone dipropionate liposome aerosol. Chest 1994; 105:106-10
11. Thomas SHL, O'Doherty MJ, Graham A, et al. Pulmonary deposition of nebulized amiloride in cystic fibrosis: comparison of two nebulisers. Thorax 1991; 46:717-21
12. O'Doherty MJ, Thomas S, Page C, et al. Pulmonary deposition of nebulised pentamidine isethionate: effect of nebuliser type, dose and volume of fill. Thorax 1990; 45:460-64
13. Mukhopadhyay S. When will nebulized chemotherapy come of age? Respir Med 1994; 88:245-47
14. Knowles MR, Church NL, Waltner WE. et al. Amiloride in cystic fibrosis: safety, pharmacokinetics, and efficacy in the treatment of pulmonary disease. In: Cragoe EJ, Kleyman TR, Simchowitz L, eds. Amiloride and its analogs: unique cation transport inhibitors. New York: VCH Publishers, 1992; 301-16
15. Hollie MC, Malone RA, Skufca RM, et al. Extreme variability in aerosol output of the DeVilbiss 646 Jet nebulizer. Chest 1991; 100:1339-40
16. Jorres R, Nowak D, Rabe K, et al. Variability in aerosol output of the DeVilbiss 646 nebulizer [letter]. Chest 1992; 102:1636
17. Schuger K. Measurement of amiloride in airway surface liquid utilizing HPLC and fluorescence detection. Biomed Chromatogr 1994; 8:219-23
18. Laird NM, Ware JH. Random effects models for longitudinal data. Biometrics 1982; 38:963-74
19. Akaike H. An information criterion. Math Sci 1976; 14:5-9
20. Smith JJ, Travis SM, Welsh MJ. Cystic fibrosis airway epithelia fail to kill bacteria because of abnormal airway surface liquid. Cell 1996; 85:229-36
21. Bowler IM, Kelman B, Worthington D, et al. Nebulised amiloride in respiratory exacerbations of cystic fibrosis: a randomised controlled trial. Arch Dis Child 1995; 73:427-30
22. + transport in cystic fibrosis epithelia: abnormal rate and response to adenyl cyclase activation. J Clin Invest 1986; 78:1245-52
23. Knowles M, Murray G, Shallal J, et al. Bioelectric properties and ion flow across excised human bronchi. J Appl Physiol 1984; 56:868-77
24. + permeability in cystic fibrosis human primary cell cultures. J Physiol (Lond) 1988; 405:77-103
25. Knowles MR, Gatzy JT, Boucher RC. Relative ion permeability of normal and cystic fibrosis nasal epithelium. J Clin Invest 1983; 71:1410-17
26. Anderson WA. Pharmacokinetics of amiloride by inhalation in adults, adolescents, and children [abstract]. Pediatr Pulmonol 1993; 9(suppl): 150-51
27. Jones K, Liao E, Hohneker KH, et al. Pharmacokinetics of amiloride after inhalation and oral administration in adolescent and adult patients with cystic fibrosis [abstract]. Pediatr Pulmonol 1993; 9A(suppl):171-72
28. Wood RE, Blair KC, Liao E, et al. Deposition of amiloride aerosol in the airways of children with CF, ages 4-11 years [abstract]. Pediatr Pulmonol 1992; 9A(suppl): Hot Science
29. Hindle M, Chrystyn H. Determination of the relative bioavailability of salbutamol to the lung following inhalation. Br J Clin Pharmacol 1992; 34:311-15
30. Summers QA, Singh S, Honeywell RG, et al. The effects of respiratory manoevres and pharmacological agents on the pharmacokinetics of nedocromil sodium after inhalation. Br J Clin Pharmacol 1992; 33:431-38
31. Hardy JG, Newman SP, Knoch M. Lung deposition from four nebulizers. Respir Med 1993; 87:461-65
32. Mukhopadhyay S, Staddon GE Eastman C, et al. The quantitative distribution of nebulized antibiotic in the lung in cystic fibrosis. Respir Med 1994; 88:203-11
33. Ilowite JS, Gorvoy JD, Smaldone GC. Quantitative deposition of aerosolized gentamycin cystic fibrosis. Am Rev Respir Dis 1987; 136:1445-49
34. Weber A, Smith A, Williams-Warren J, et al. Nebulizer delivery of tobramycin to the lower respiratory tract. Pediatr Pulmonol 1994; 17:331-39
35. O'Doherty MJ, Thomas S, Page C, et al. Differences in relative efficiency of nebulisers for pentamidine administration. Lancet 1988; 2:1283-86
36. Hofmann T, Ziersch A, Senier I, et al. Benzamil and amiloride in CF nasal epithelium: time course of the effects on nasal potential difference in vivo [abstract]. Pediatr Pulmonol 1996; 13 (suppl):254
37. Blank U, Hofmann T, Clauss W, et al. Different blocker kinetics of amiloride and phenamil on epithelial sodium conductances in cystic fibrosis nasal epithelium [abstract]. Pediatr Pulmonol 1996; 13 (suppl):255
38. Rennard SI, Basset G, Lecossier D, et al. Estimation of the volume of epithelial lining fluid using urea as a marker of dilution. J Appl Physiol 1986; 60:532-38
39. Von Wichert P, Joseph K, Muller B, et al. Bronchoalveolar lavage: quantitation of intraalveolar fluid? Am Rev Respir Dis 1993; 147:148-52
40. Chinard FP. Quantitative assessment of epithelial lining fluid in the lung. Am J Physiol 1992; 263:L617-18
41. Restrick LJ, Sampson AP, Piper PJ, et al. Inulin as a marker of dilution of bronchoalveolar lavage in asthmatics and normal subjects. Am J Respir Crit Care Med 1995; 151:1211-17
42. App EM, King M, Helfesrieder R, et al. Acute and long term amiloride inhalation in cystic fibrosis lung disease: a rational approach to cystic fibrosis therapy. Am Rev Respir Dis 1990; 141:605-12
43. Noone PG, Bennett WD, Zeman KL, et al. Cough clearance in patients with primary ciliary dyskinesia: effects of aerosolized uridine-5′-triphosphate and amiloride [abstract]. Am J Respir Crit Care Med 1995; 151:A464